文献速递角膜与眼表疾病青光眼

DMEK与DSAEK术后新发青光眼及高眼压发生率:系统综述与荟萃分析

Incidence of De Novo Glaucoma and Ocular Hypertension After DMEK Versus DSAEK: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Ophthalmol · 2026-09-22

DMEK组新发青光眼3%对DSAEK组11%,OHT为9%对34%,用药启动/升级为6%对20%(均P≤.0006),但证据确定性低至极低。

要点

  • DMEK术后新发青光眼、OHT及用药启动/升级的合并发生率均低于DSAEK。
  • DSAEK随访时间约为DMEK两倍,泊松率比仍偏向DMEK。
  • 仅按视神经或视野标准定义青光眼时,两组差异缩小至无统计学意义。

核心结论

  • 内皮角膜移植术后新发青光眼和OHT常见,DMEK术后事件率总体低于DSAEK,但技术本身贡献的大小仍不确定。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、MEDLINE、Cochrane CENTRAL、CINAHL、Web of Science、Scopus和ProQuest自建库至2025年6月。
  • 采用随机效应模型合并单臂发生率及头对头比值比,并行每眼年发生率(泊松)和针对移植类型与激素暴露的荟萃回归,证据确定性用GRADE评估。

主要发现

  • DMEK与DSAEK的新发青光眼合并发生率分别为3%与11%,OHT为9%与34%,用药启动/升级为6%与20%(所有P≤.0006)。
  • 青光眼手术发生率DMEK为1.0%、DSAEK为2.5%(P=.14)。
  • DSAEK队列随访时间约为DMEK两倍(68 vs 35个月),但泊松率比仍偏向DMEK:青光眼0.45(95%CI 0.19-1.07),OHT 0.31(95%CI 0.14-0.71)。
  • 将青光眼限制为视神经或视野标准后,发生率变为5.0% vs 8.1%(P=.38),且激素暴露更高与OHT独立相关。
  • 头对头估计偏向DMEK但无统计学意义(OR 0.51,95%CI 0.22-1.21),所有随机试验均使用超薄或微薄DSAEK。

关键数值与推荐

  • DMEK vs DSAEK新发青光眼3% vs 11%,OHT 9% vs 34%,用药启动/升级6% vs 20%(均P≤.0006)。
  • 青光眼手术1.0% vs 2.5%(P=.14)。
  • 泊松率比:青光眼0.45(95%CI 0.19-1.07),OHT 0.31(95%CI 0.14-0.71)。
  • 视神经或视野标准定义青光眼:5.0% vs 8.1%(P=.38)。
  • 头对头OR 0.51(95%CI 0.22-1.21)。

临床怎么用

  • 选择内皮角膜移植术式时可参考DMEK术后青光眼及OHT事件率较低的合并估计。
  • 术后监测应关注激素暴露相关OHT风险,尤其DSAEK术后。
  • 因证据确定性低至极低且定义不一,不宜仅凭此估计制定刚性随访阈值。

局限性

  • 青光眼定义不一,影响发生率估计的可比性。
  • 激素暴露存在混杂,且随机证据仅限超薄或微薄DSAEK。
  • 证据确定性经GRADE评估为低至极低,头对头比较无统计学意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: Postkeratoplasty glaucoma complicates endothelial keratoplasty, but its incidence with modern techniques remains uncertain. We conducted a systematic review estimating the pooled incidence of de novo glaucoma and ocular hypertension (OHT) in glaucoma-naïve adult eyes undergoing Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping automated endothelial keratoplasty (DSAEK). CLINICAL RELEVANCE: Postkeratoplasty glaucoma threatens optic nerve function and graft survival and may require therapy or surgery. Surgeons lack procedure-specific estimates to guide procedure selection and postoperative surveillance. METHODS: We searched Embase, MEDLINE, Cochrane CENTRAL, CINAHL, Web of Science, Scopus, and ProQuest from inception to June 2025. Eligible studies enrolled adult eyes without pre-existing glaucoma undergoing DMEK or DSAEK and reported postoperative de novo glaucoma and/or OHT. Two reviewers screened and appraised studies; all counts were re-audited against source articles. Random-effects models pooled single-arm incidences by procedure and head-to-head odds ratios, with incidence rates per eye-year (Poisson) and meta-regression on keratoplasty type and steroid exposure. Certainty was evaluated using GRADE. RESULTS: Thirty-three studies including 5235 eyes met inclusion criteria. Pooled incidence after DMEK vs DSAEK was 3% vs 11% for de novo glaucoma, 9% vs 34% for OHT, and 6% vs 20% for medication initiation/escalation (all P ≤ .0006); glaucoma surgery 1.0% vs 2.5% (P = .14). DSAEK cohorts were followed twice as long (68 vs 35 months), but Poisson rate ratios still favored DMEK (glaucoma 0.45, 95% CI 0.19-1.07; OHT 0.31, 0.14-0.71). Restricting glaucoma to optic-nerve or visual-field criteria narrowed this to 5.0% vs 8.1% (P = .38), and greater steroid exposure was independently associated with OHT. Head-to-head estimates favored DMEK but were nonsignificant (OR 0.51, 0.22-1.21); every randomized trial used ultrathin or microthin DSAEK. Certainty was low to very low. CONCLUSION: De novo glaucoma and OHT are common after endothelial keratoplasty, and the overall pattern of lower event rates after DMEK persisted after adjustment for observation time. The magnitude attributable to technique remains uncertain, given variable glaucoma definitions, confounding by steroid exposure, and randomized evidence limited to ultrathin or microthin DSAEK. Larger head-to-head studies with standardized definitions and steroid protocols are needed.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sadek K, Yu P, Al-Ani A, et al. Incidence of De Novo Glaucoma and Ocular Hypertension After DMEK Versus DSAEK: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2026. PMID: 42772430. doi:10.1016/j.ajo.2026.09.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。